跳至主要内容
临床试验/NCT05357690
NCT05357690已完成2 期

Stellate Ganglion Blockade for the Prevention of Atrial Fibrillation After Cardiac Surgery: A Randomized Placebo-Controlled Trial

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年4月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Mayo Clinic
入组人数
200
试验地点
2
主要终点
Incidence of atrial fibrillation

研究概览

简要总结

The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease other types of abnormal heart rhythms as well as decrease the chance of atrial fibrillation.

详细描述

The investigator hypothesizes that stellate ganglion blockade with local anesthetic performed prior to cardiac surgery will reduce the incidence and duration of postoperative atrial fibrillation (POAF).

Specific Aim 1: Determine the incidence of POAF in patients receiving pre-surgical stellate ganglion blockade with local anesthetic versus saline placebo within one week of surgery or during hospitalization if discharged prior to one week.

Specific Aim 2: Determine the duration of POAF in patients receiving pre-surgical stellate ganglion blockade with local anesthetic versus saline placebo within one week of surgery or during hospitalization if discharged prior to one week.

Specific Aim 3: Determine the success rate of the block as evaluated by ipsilateral hand temperature change and skin sympathetic nerve activity (SKNA).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient presenting for cardiac surgery at the Mayo Clinic in Rochester, Minnesota.
  • Patients scheduled to undergo mitral or aortic valve surgery with or without coronary artery bypass grafting.

排除标准

  • Patients with a history of permanent atrial fibrillation, left or right ventricular assist device implantation or explantation.
  • Patients with procedures not requiring cardiopulmonary bypass.
  • Patients with procedures requiring deep hypothermic circulatory arrest.
  • Patients with active infection or sepsis.
  • Pre-operative immunosuppressive medication use (including steroid use).
  • Pre-operative anti-arrhythmic medication use (aside from beta-blockers).
  • Patients with Immunodeficiency syndrome.
  • Patients with known neurologic disorder.
  • Patients requiring left internal jugular central line placement.
  • Performance of Maze procedures or left atrial appendage ligation procedures will not exclude patients from potential enrollment as atrial fibrillation still occurs postoperatively while the scarring from the Maze procedure forms.

研究组 & 干预措施

Stellate ganglion block with local anesthetic

Experimental

Subjects will receive a single injection of bupivacaine in a stellate ganglion block

干预措施: Stellate ganglion block (Procedure)

Stellate ganglion block with local anesthetic

Experimental

Subjects will receive a single injection of bupivacaine in a stellate ganglion block

干预措施: Bupivacaine (Drug)

Stellate ganglion block with saline placebo

Sham Comparator

Subjects will receive a single injection of saline in a stellate ganglion block

干预措施: Stellate ganglion block (Procedure)

Stellate ganglion block with saline placebo

Sham Comparator

Subjects will receive a single injection of saline in a stellate ganglion block

干预措施: Placebo (Drug)

结局指标

主要结局

Incidence of atrial fibrillation

时间窗: Within one week of surgery or during hospitalization if discharged prior to one week

Percentage of subjects to experience postoperative atrial fibrillation (POAF)

次要结局

  • Duration of atrial fibrillation(Within one week of surgery or during hospitalization if discharged prior to one week)
  • Skin Sympathetic Nerve Activity(10-30 minute following performance of nerve block)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Erica D. Wittwer, M.D., Ph.D.

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验